Physician profile
Nithan Narendra
NPI 1457531873
$98,693.30
in general payments reported to CMS, 2019-2025
7 companies · $9,256 in 2025
The $9,256 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $15K · 2021: $8,142 · 2022: $11K · 2023: $15K · 2024: $6,112 · 2025: $9,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $3,155 · Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,000.00 |
| Travel and Lodging | $3,154.93 |
| Food and Beverage | $2,153.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $97,484.04 | 2019-2025 | |
| Gilead Sciences, INC. | $467.68 | 2019-2025 | Epclusa |
| Intercept Pharmaceuticals, INC. | $255.71 | 2019-2020 | |
| Madrigal Pharmaceuticals | $193.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Palette Life Sciences, INC. | $144.80 | 2020 | |
| Aurinia Pharma U.S., INC. | $107.84 | 2023 | |
| Intra-Sana Laboratories | $40.18 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nithan Narendra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.